GlassScriptPhysician profile
Reed I Ward
NPI 1235217506
$1,749.96
in general payments reported to CMS, 2019-2025
29 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $164 · 2021: $238 · 2022: $205 · 2023: $311 · 2024: $281 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.49 | 2021-2024 | Ubrelvy, Vraylar |
| Amgen INC. | $181.81 | 2019-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $180.85 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $176.04 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $165.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $100.57 | 2020-2024 | Veozah |
| Insulet Corporation | $81.83 | 2025 | Omnipod |
| Ossur Americas, INC. | $62.84 | 2025 | |
| Pfizer INC. | $53.03 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $50.46 | 2024-2025 | Voquezna |
| Horizon Therapeutics Plc | $42.78 | 2019-2020 | |
| Boston Scientific Corporation | $37.38 | 2023-2025 | General - Pain Management |
| Teva Pharmaceuticals USA, INC. | $35.77 | 2019-2020 | |
| Genzyme Corporation | $31.77 | 2019 | |
| Lilly USA, LLC | $28.96 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $21.07 | 2025 | Nimbl, Flexitouch Plus |
| Mylan Specialty L.P. | $20.72 | 2024 | Yupelri |
| Genentech USA, INC. | $19.68 | 2022 | |
| Krystal Biotech INC | $18.17 | 2024 | Vyjuvek |
| Nestle Healthcare Nutrition INC. | $16.87 | 2021 | |
| Exact Sciences Corporation | $16.41 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.61 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.21 | 2021 | |
| Janssen Biotech, INC. | $14.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.01 | 2024 | Amvuttra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.24 | 2019 | |
| Therapeuticsmd, INC. | $13.22 | 2022 | |
| Amarin Pharma, INC. | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.